二甲双胍联合ADT治疗前列腺癌的代谢与肿瘤学效应:系统评价与荟萃分析(含STAMPEDE)
该系统评价与荟萃分析纳入6项RCT共2415例前列腺癌患者,评估二甲双胍联合ADT对比ADT单用的代谢与肿瘤学效应。12个月时二甲双胍显著降低腰围、HbA1c和空腹血糖,但体重和LDL胆固醇无显著变化;STAMPEDE中总生存无显著改善,高瘤负荷亚组显示生存获益但交互作用不显著;MANSMED中CRPC无进展生存显著延长但证据来自单一小样本开放标签试验。
要点
- 二甲双胍联合ADT在12个月时显著降低腰围、HbA1c和空腹血糖。
- STAMPEDE中二甲双胍未显著改善总生存,高瘤负荷亚组生存获益假设需前瞻性验证。
- MANSMED显示CRPC无进展生存显著延长,但证据来自单一小样本开放标签试验。
核心结论
- 二甲双胍联合ADT可中等确定性降低腰围和HbA1c。
- 未经选择患者中未证实肿瘤学获益;STAMPEDE高瘤负荷亚组信号来自单一试验,需前瞻性按瘤负荷分层RCT验证。
研究设计与样本
- PRISMA 2020指导的系统评价与荟萃分析(PROSPERO CRD420261384520),检索5个数据库至2026年5月12日。
- 疾病状态从转移性(STAMPEDE、Alagizy、多数MANSMED)到局部晚期或生化复发(PREMIUM、PRIME、Mahalingam);除MANSMED(约20%)外均排除糖尿病。
- 采用随机效应模型及Hartung-Knapp校正,GRADE评估证据确定性。
主要发现
- 12个月时二甲双胍显著降低腰围(MD -1.12 cm;p=0.014)、HbA1c(MD -0.070%;p=0.029)和空腹血糖(MD -0.100 mmol/L;p=0.031)。
- 体重和LDL胆固醇降低不显著(MD -1.60 kg;p=0.090和MD -0.130 mmol/L;p=0.343)。
- STAMPEDE中二甲双胍未改善总生存(HR 0.91;p=0.15);高瘤负荷亚组显示生存获益(HR 0.79;p=0.007;瘤负荷交互作用p=0.12,不显著)。
- MANSMED中CRPC无进展生存显著延长(HR 0.50;p=0.01),但该信号来自单一小样本开放标签试验。
关键数值与推荐
- 主要代谢结局为体重、腰围、HbA1c、空腹血糖和LDL胆固醇;次要(探索性)肿瘤学结局为总生存和CRPC无进展生存,主要源自单一试验。
- 纳入标准为比较二甲双胍联合ADT与ADT单用的RCT。
临床怎么用
- 二甲双胍联合ADT可考虑用于改善代谢指标(腰围、HbA1c、空腹血糖),但肿瘤学获益未经选择患者中未证实。
- STAMPEDE高瘤负荷亚组生存信号需前瞻性按瘤负荷分层RCT验证后方可指导临床决策。
局限性
- 肿瘤学结局主要源自单一试验,MANSMED的CRPC无进展生存信号来自单一小样本开放标签试验。
- STAMPEDE高瘤负荷亚组瘤负荷交互作用p=0.12,不显著,结果属假设生成性。
- 多数试验排除糖尿病患者,MANSMED中约20%为糖尿病患者,代谢结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Androgen-deprivation therapy (ADT) is the cornerstone of advanced prostate cancer treatment but induces a metabolic syndrome phenotype that heightens cardiovascular risk. Metformin, an insulin-sensitising biguanide with emerging anticancer properties, is a rational ADT adjunct. Following STAMPEDE's 2025 publication, we aimed to quantify metformin's metabolic benefit and characterise its oncological signal by disease volume. METHODS: This PRISMA 2020-guided review (PROSPERO CRD420261384520) searched five databases through 12 May 2026. Eligible RCTs compared metformin plus ADT versus ADT alone in prostate cancer. Primary metabolic outcomes were body weight, waist circumference, HbA1c, fasting glucose, and LDL cholesterol. Secondary (exploratory) oncological outcomes were overall survival (OS) and castration-resistant prostate cancer-free survival (CRPC-FS), derived predominantly from a single trial. Random-effects models with Hartung-Knapp correction were used; GRADE assessed certainty. RESULTS: Six trials enroling 2415 participants (78% from STAMPEDE) were included: STAMPEDE (n = 1 874), PRIME (n = 166), PREMIUM (n = 83), MANSMED (n = 124), Mahalingam (n = 36), and Alagizy (n = 132). Disease status ranged from metastatic (STAMPEDE, Alagizy, majority MANSMED) to locally advanced or biochemically recurrent (PREMIUM, PRIME, Mahalingam); all excluded diabetes mellitus except MANSMED ( ~ 20%). At 12 months, metformin significantly reduced waist circumference (MD -1.12 cm; p = 0.014), HbA1c (MD -0.070%; p = 0.029), and fasting glucose (MD -0.100 mmol/L; p = 0.031). Body weight and LDL cholesterol reductions were non-significant (MD -1.60 kg; p = 0.090 and MD -0.130 mmol/L; p = 0.343, respectively). In STAMPEDE, metformin did not improve OS (HR 0.91; p = 0.15); the high-volume subgroup showed a survival benefit (HR 0.79; p = 0.007; volume interaction p = 0.12, non-significant). In MANSMED, CRPC-free survival was significantly prolonged (HR 0.50; p = 0.01), though this signal derives from a single small, open-label trial. CONCLUSIONS: Metformin added to ADT produces moderate-certainty reductions in waist circumference and HbA1c. Oncological benefit in unselected patients was not demonstrated; the hypothesis-generating STAMPEDE high-volume subgroup signal, derived from a single trial, warrants evaluation in a prospective, volume-stratified RCT.
引用
- Fakhri F, Alkhairi Z, Sarhan T, et al. Metabolic and oncological effects of metformin added to ADT in prostate cancer: systematic review and meta-analysis including STAMPEDE. Prostate Cancer Prostatic Dis. 2026. PMID: 42875601. doi:10.1038/s41391-026-01165-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。